Stock Detail
NEKTAR THERAPEUTICS
Drug Delivery
NKTR @ Yahoo Finance | NKTR Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $4.28 | $4.38 | $-0.16 | -3.60% | 0.00 | $4.44 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $4.37 | $4.26 | 1.2M | 489.73M | 1.2M | -3.89 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 4.43 | 4.36 | 4.31 | 4.24 | 4.19 |
Stock Profile
Nektar Therapeutics provides a portfolio of drug delivery solutions that enable the development of pharmaceutical products. The company focuses on three technology platforms: Nektar Advanced PEGylation Technology, Nektar Pulmonary Technology, and Nektar Supercritical Fluid Technology. The Nektar Advanced PEGylation Technology uses PEGylation chemistry and a PEG-based delivery system in various drug classes, including macromolecules, such as peptides and proteins, as well as small sized molecular compounds and other drugs. The Nektar Pulmonary Technology uses its know-how and technology in drug formulation, powder processing, powder filling, and packaging and devices to create an integrated system to reproducibly deliver therapeutics to the lung for both systemic and local lung applications. The Nektar Supercritical Fluid Technology uses a particle engineering process, which yields consistent powder particles in terms of size, shape, and morphology that incorporates into various dosage forms, including tablets, capsules, and inhalation systems. The company's product pipeline consists of 6 products approved in the United States; 1 product approved in Europe and in late-stage development in the United States; 3 products in phase III clinical trials; 1 product in phase II clinical trial; and 10 products in phase I clinical trials. It has strategic alliance with Enzon Pharmaceuticals, Inc. The company also has collaboration agreement with Alliance Pharmaceutical Corp.; Straumann Group; Unimed Pharmaceuticals, Inc.; Pfizer, Inc.; Schering-Plough Corporation; Baxter International, Inc.; and Eyetech Pharmaceuticals, Inc. Nektar serves pharmaceutical and biotechnology companies located in the United States and Europe. The company was founded as Inhale Therapeutic Systems, Inc. by John S. Patton in 1990 and changed its name to Nektar Therapeutics in 2003. Nektar is headquartered in San Carlos, California.